CHKA, known to be overexpressed in a variety of cancers and associated with the PI3K/AKT signaling pathway 18, 19, was found to be downregulated after CQ treatment, leading to a significant reduction in PI3K and AKT phosphorylation and tumor cell proliferation. The gene discussed is AKT1; the disease is cancer.